BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26595461)

  • 1. CRISPR-Cas9-based target validation for p53-reactivating model compounds.
    Wanzel M; Vischedyk JB; Gittler MP; Gremke N; Seiz JR; Hefter M; Noack M; Savai R; Mernberger M; Charles JP; Schneikert J; Bretz AC; Nist A; Stiewe T
    Nat Chem Biol; 2016 Jan; 12(1):22-8. PubMed ID: 26595461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
    Xie X; He G; Siddik ZH
    Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
    Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
    Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
    Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
    Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
    Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
    Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.
    Spinnler C; Hedström E; Li H; de Lange J; Nikulenkov F; Teunisse AF; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
    Cell Death Differ; 2011 Nov; 18(11):1736-45. PubMed ID: 21546907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
    Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation.
    Ma T; Yamada S; Ichwan SJ; Iseki S; Ohtani K; Otsu M; Ikeda MA
    Biochem Biophys Res Commun; 2012 Jan; 417(3):931-7. PubMed ID: 22166212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
    Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
    Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation.
    Valentine JM; Kumar S; Moumen A
    BMC Cancer; 2011 Feb; 11():79. PubMed ID: 21338495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Shin D; Kim EH; Lee J; Roh JL
    Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
    Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
    Hou J; Cao X; Cheng Y; Wang X
    Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.
    Davaadelger B; Shen H; Maki CG
    PLoS One; 2014; 9(11):e110844. PubMed ID: 25380055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of Daxx by ATM contributes to DNA damage-induced p53 activation.
    Tang J; Agrawal T; Cheng Q; Qu L; Brewer MD; Chen J; Yang X
    PLoS One; 2013; 8(2):e55813. PubMed ID: 23405218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of p53 in cancer drug resistance and targeted chemotherapy.
    Hientz K; Mohr A; Bhakta-Guha D; Efferth T
    Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
    Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
    Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mdm2 links genotoxic stress and metabolism to p53.
    Wang Z; Li B
    Protein Cell; 2010 Dec; 1(12):1063-72. PubMed ID: 21213101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.